Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Regenerative Device Helps Rescue Failing Organs

By HospiMedica International staff writers
Posted on 22 Aug 2017
Innovative tissue nanotransfection (TNT) technology can treat diseased organs by injecting genetic code into living skin cells in order to change their function, claims a new study.

Developed at Ohio State University (OSU, Columbus, USA), TNT technology involves two major components - a nano-channelled chip for specific cytosolic delivery of non-viral reprogramming factors to adult cells in the live body, and the cargo (DNA or RNA) itself. More...
Delivery of the cargo is achieved by applying a highly intense, focused electric field through the arrayed nano-channels, which benignly nanoporates the juxtaposing tissue cell membranes and electrophoretically drives the reprogramming factors into the cells.

The researchers demonstrated the simplicity of the approach by rescuing necrotizing tissues and whole limbs in two murine models of injury-induced ischemia. In the study, reprogrammed skin cells converted to vascular cells in badly injured ischemic legs. Within one week, active blood vessels appeared, and by the second week the leg was saved. In laboratory tests, the technology was also shown to reprogram skin cells in the living body into nerve cells that were then injected into brain-injured mice to help them recover from an induced stroke. The study was published on August 7, 2017, in Nature Nanotechnology.

“By using our novel nanochip technology, injured or compromised organs can be replaced. We have shown that skin is a fertile land where we can grow the elements of any organ that is declining,” said senior author Chandan Sen, MD, PhD, of the OSU Center for Regenerative Medicine and Cell Based Therapies. “With this technology, we can convert skin cells into elements of any organ with just one touch. This process only takes less than a second and is non-invasive, and then you're off. The chip does not stay with you, and the reprogramming of the cell starts.”

Current gene therapy involves a vector, usually a virus, genetically engineered to deliver the gene by infecting the cell. Some types of virus, such as retroviruses, integrate their genetic material (including the new gene) into a chromosome in the human cell. Other viruses, such as adenoviruses, introduce their DNA into the nucleus of the cell, but the DNA is not integrated into a chromosome. The vector can be injected directly into a specific tissue in the body, where it is taken up by individual cells. Alternately, a sample of the patient's cells can be removed and exposed to the vector in a laboratory setting and then returned to the patient.

Related Links:
Ohio State University


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.